Haemonetics (HAE) Stock Forecast & Price Target

Haemonetics Corp demonstrated a significant improvement in its financial metrics, with the adjusted operating margin in the plasma business increasing by 60 basis points to 36.2%. The company achieved compelling organic growth of 20.2% in its plasma segment, indicative of robust market demand and effective market share gains. Furthermore, Haemonetics raised its free cash flow expectations to a range of $200-220 million, reflecting increased operational efficiency and overall financial health across all segments.

Haemonetics Corp reported a significant decline of 19.6% in revenue, heavily influenced by divestiture activity, while organic growth was only marginal at 2.8% for the same period, indicating potential issues in sustaining growth momentum. The company's financial guidance for FY/26 anticipates a reported revenue decline of 1% to 4%, with organic growth (excluding CSL impacts) projected at 7% to 10%, which may not sufficiently offset underlying weaknesses in the blood center segment constrained by fierce competition. Furthermore, the significant declines in the interventional technologies segment, with an 11.6% organic decline, and a downturn in core growth drivers, underline challenges that could hinder Haemonetics's overall profitability and market position.